The monoclonals: What have we learned and where are we going?

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• The first biologic for allergic and immunologic diseases was approved in 2003, marking the beginning of the monoclonal antibody era.
• Monoclonal antibodies have since become crucial in understanding disease pathogenesis and developing targeted therapies.

Purpose of the Study:

• To review technological advancements enhancing monoclonal antibody utility in allergic and respiratory disease management.
• To explore emerging strategies and targets for next-generation antibody therapies.

Main Methods:

• Review of technological updates in monoclonal antibody development.
• Analysis of innovations including humanization, biosimilars, Fc portion mutations, bispecific/trispecific antibodies, nanobodies, antibody drug conjugates, and protein degradation techniques.

Main Results:

• Technological improvements have led to more effective monoclonal antibodies with longer action durations.
• Emerging therapies target IgE, mast cells, and other key pathogenic factors.
• Current antibodies aid in understanding disease and identifying new therapeutic targets.

Conclusions:

• Next-generation monoclonal antibodies are expected to offer enhanced safety, longevity, and efficacy.
• Further research into biomarkers and outcomes data is necessary for personalized treatment matching.